Pegylated interferon-α2b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 95, Issue 3, 2012, Pages

  Yagyu, Hiroaki ^a   Okada, Kenta ^a   Sato, Shin ^a   Yamashita, Yumiko ^a   Okada, Nobukazu ^a   Osuga, Jun Ichi ^a   Nagasaka, Shoichiro ^a   Sugano, Kentaro ^a   Ishibashi, Shun ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Hashitoxicosis; Interferon ; Ribavirin; Type 1 diabetes mellitus

Indexed keywords

ALPHA INTERFERON; GLUCOSE; HEMOGLOBIN A1C; LEVOTHYROXINE SODIUM; LIOTHYRONINE; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; THYROGLOBULIN ANTIBODY; THYROID ANTIBODY; THYROTROPIN; THYROXINE; VIRUS RNA;

ADULT; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; THYROTOXICOSIS;

DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; HASHIMOTO DISEASE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; THYROTOXICOSIS;

EID: 84857239099     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.11.016     Document Type: Article

References (20)

1. Harris D.M., Hespenheide E.E., Dalkin A.C., Kirk S.E., Ellis D.S., Caldwell S.H. Hyperthyroidism with interferon-ribavirin therapy for hepatitis C: a case report and proposed treatment algorithm. Am J Gastroenterol 2000, 95:2995-2996.
2. Hayashi M., Kataoka Y., Tachikawa K., Koguchi H., Tanaka H. Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Diabetes Res Clin Pract 2009, 86:e19-e21.
3. Soultati A.S., Dourakis S.P., Alexopoulou A., Deutsch M., Archimandritis A.J. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007, 13:1292-1294.
4. Hoofnagle J.H., Mullen K.D., Jones D.B., Rustgi V., Di Bisceglie A., Peters M., et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986, 315:1575-1578.
5. Mandac J.C., Chaudhry S., Sherman K.E., Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006, 43:661-672.
6. Preziati D., La Rosa L., Covini G., Marcelli R., Rescalli S., Persani L., et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995, 132:587-593.
7. Roti E., Minelli R., Giuberti T., Marchelli S., Schianchi C., Gardini E., et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996, 101:482-487.
8. Fabris P., Betterle C., Floreani A., Greggio N.A., de Lazzari F., Naccarato R., et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992, 340:548.
9. Ogihara T., Katagiri H., Yamada T., Kudo H., Imai J., Ishigaki Y., et al. Peginterferon (PEG-IFN) plus ribavirin combination therapy, but neither interferon nor PGE-IFN alone, induced type 1 diabetes in a patient with chronic hepatitis C. Intern Med 2009, 48:1387-1390.
10. Okanoue T., Sakamoto S., Itoh Y., Minami M., Yasui K., Sakamoto M., et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996, 25:283-291.
11. Uto H., Matsuoka H., Murata M., Okamoto T., Miyata Y., Hori T., et al. A case of chronic hepatitis C developing insulin-dependent diabetes mellitus associated with various autoantibodies during interferon therapy. Diabetes Res Clin Pract 2000, 49:101-106.
12. Fattovich G., Giustina G., Favarato S., Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996, 24:38-47.
13. Koivisto V.A., Pelkonen R., Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989, 38:641-647.
14. Devendra D., Eisenbarth G.S. Interferon alpha - a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol 2004, 111:225-233.
15. Foulis A.K., Interferon-alpha IDDM: comment. Diabetologia 1996, 39:127.
16. Mazziotti G., Sorvillo F., Piscopo M., Morisco F., Cioffi M., Stornaiuolo G., et al. Innate and acquired immune system in patients developing interferon-alpha-related autoimmune thyroiditis: a prospective study. J Clin Endocrinol Metab 2005, 90:4138-4144.
17. Prummel M.F., Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003, 13:547-551.
18. International Expert Committee International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009, 32:1327-1334.
19. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl 1):S62-S69.
20. Cramp M.E., Rossol S., Chokshi S., Carucci P., Williams R., Naoumov N.V., et al. C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000, 118:346-355.